Research Catalog

Follow-on biologics hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.

Title
Follow-on biologics [microform] : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.
Author
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions.
Publication
Washington : U.S. G.P.O., 2008.

Details

Description
iv, 78 p.; 24 cm.
Series Statement
  • S. hrg. ; 110-375
  • United States. Congress. Senate. S. hrg ; 110-375.
Subject
  • Pharmaceutical biotechnology > Government policy > United States
  • Pharmaceutical biotechnology > United States > Patents
  • Pharmaceutical technology > Government policy > United States
  • Drug development > Government policy > United States
Note
  • Shipping list no.: 2009-0285-M.
  • Paper version available for sale by the Supt. of Docs., U.S. G.P.O.
Bibliography (note)
  • Includes bibliographical references.
Reproduction (note)
  • Microfiche.
Call Number
GPO Microfiche Y 4.L 11/4:S.HRG.110-375
OCLC
marcive464618706
Author
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions.
Title
Follow-on biologics [microform] : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.
Imprint
Washington : U.S. G.P.O., 2008.
Series
S. hrg. ; 110-375
United States. Congress. Senate. S. hrg ; 110-375.
Bibliography
Includes bibliographical references.
Reproduction
Microfiche. [Washington, D.C.] : Supt. of Docs., U.S. G.P.O., [2009]. 1 microfiche : negative.
Other Form:
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Follow-on biologics iv, 78 p. (OCoLC)272403831
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Follow-on biologics iv, 78 p. (OCoLC)272396761
Gpo Item No.
1043-B (MF)
Sudoc No.
Y 4.L 11/4:S.HRG.110-375
View in Legacy Catalog